USCOM LIMITED — Investor Presentation 2017

Jan 15, 2017

==> picture [101 x 122] intentionally omitted <==

==> picture [244 x 44] intentionally omitted <==

==> picture [183 x 40] intentionally omitted <==

==> picture [135 x 39] intentionally omitted <==

Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO

==> picture [960 x 42] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

==> picture [227 x 53] intentionally omitted <==

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

==> picture [61 x 73] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

==> picture [172 x 53] intentionally omitted <==

"Uscom is a leading innovator in cardiovascular and pulmonary medical devices, developing new technologies to address the challenges of global disease and health care. Uscom is driven by a commercial ambition to become a leader in global health business.”

==> picture [61 x 73] intentionally omitted <==

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [441 x 53] intentionally omitted <==

==> picture [107 x 128] intentionally omitted <==

Growth by acquisition

==> picture [280 x 56] intentionally omitted <==

Acquired 2013

==> picture [148 x 65] intentionally omitted <==

Acquired 2015

==> picture [61 x 73] intentionally omitted <==

Incremental shareholder value Two companies Pulsecor – 2013 Thor – 2015

Two product suites BP+

SpiroSonic

Two global revenue streams starting 2017 IP and product reservoir

World leading technologies Stand alone companies Growth strategy Efficiencies of scale Investment Operational integration Product development Regulatory Revenue - 2017

Uscom – devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [250 x 53] intentionally omitted <==

“Digital medical device innovations to improve the physician experience and patient outcomes.”

Digital Doppler Ultrasound

==> picture [161 x 161] intentionally omitted <==

Suprasystolic Oscillometry

==> picture [261 x 186] intentionally omitted <==

Digital Transit time Ultrasound

==> picture [61 x 73] intentionally omitted <==

New generation digital cardiovascular pulmonary devices.

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [267 x 52] intentionally omitted <==

Sector leading technologies

Fluid, Sepsis

& Heart Failure

• US $1.3bn market[*]

• CAGR of 7.6%[*]

• CE, FDA, TGA, CFDA

Hypertension & Vascular Health

• US $1.7bn market[*]

• CAGR of 11.5%[*]

• CE, FDA, TGA

COPD

& Asthma

• US $400m market[*]

• CAGR of 6.5%[*]

• CE, TGA, FDA

==> picture [61 x 73] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

USCOM 1A

Cardiac Output Monitoring

==> picture [156 x 161] intentionally omitted <==

• Source: MedTech Insight; Transparency Market Research

BP+

Blood Pressure Monitoring

==> picture [161 x 161] intentionally omitted <==

==> picture [192 x 119] intentionally omitted <==

Uscom – Devices the experts use

SpiroSonic Pulmonary Monitoring

==> picture [960 x 35] intentionally omitted <==

==> picture [216 x 53] intentionally omitted <==

outcomes

36 new publications in 2016

Outcomes Changes

==> picture [61 x 73] intentionally omitted <==

==> picture [602 x 279] intentionally omitted <==

----- Start of picture text -----

120
100 100 100 100
100
80
66
% 60 ACCM+echo
50
ACCM+echo + NE/USCOM
42
40
25
20
0
Fluid - 6hrs Fluid Bal 24hrs Invasive Ventilation days PICU days
----- End of picture text -----

Changing the lives of children with septic shock in India

Ranjit S, Natraj R, Kandath SK, Kissoon N, Ramakrishnan B, Marik P. Early nor-epinephrine decreased fluid and ventilatory requirements in paediatric septic shock. Indian J Crit Care Med 2016;20:561-9.

==> picture [960 x 35] intentionally omitted <==

==> picture [342 x 53] intentionally omitted <==

==> picture [119 x 53] intentionally omitted <==

==> picture [61 x 73] intentionally omitted <==

==> picture [487 x 390] intentionally omitted <==

Uscom devices address conditions responsible for 80% of leading causes of death worldwide (WHO criteria). Heart failure, sepsis, hypertension, asthma, COPD.

http://www.who.int/mediacentre/factsheets/fs310/en/ - accessed 4[th] Aug 2016

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [271 x 53] intentionally omitted <==

Total Revenue

Receipts from Customers

==> picture [885 x 274] intentionally omitted <==

----- Start of picture text -----

$3,500,000
2,563,145
2,500,000
$2,936,504
$3,000,000
2,000,000
$2,500,000
$2,039,426
$2,000,000
1,500,000
1,321,080
$
$1,500,000 $1,377,716
1,000,000
$1,010,942 829,424
$1,000,000 $864,099
621,253
500,000
$500,000
$0 -
2012 2013 2014 2015 2016 2013 2014 2015 2016
----- End of picture text -----

==> picture [61 x 73] intentionally omitted <==

Total revenue +44% to $2.94m

Receipts from Customers +94% to $2.56m

A year of growth and investment

==> picture [960 x 35] intentionally omitted <==

==> picture [271 x 52] intentionally omitted <==

Quarterly Total Revenue

Quarterly Cash Receipts

==> picture [440 x 287] intentionally omitted <==

----- Start of picture text -----

900000
800000
700000
600000
500000
$
400000
300000
200000
100000
0
Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16
----- End of picture text -----

==> picture [453 x 283] intentionally omitted <==

----- Start of picture text -----

700,000
600,000
500,000
400,000
$
300,000
200,000
100,000
0
Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16
----- End of picture text -----

==> picture [61 x 73] intentionally omitted <==

Revenue 3yr CAGR 43%

A year of growth and investment

Cash Receipts 3 yr CAGR 60%

==> picture [960 x 35] intentionally omitted <==

==> picture [271 x 52] intentionally omitted <==

Cash, Equity and Assets

==> picture [61 x 73] intentionally omitted <==

==> picture [589 x 312] intentionally omitted <==

----- Start of picture text -----

6,000,000 5,711,746
4,937,991
5,000,000
4,000,000
2,936,355
$ 3,000,000 2,839,773 2015
2016
2,288,661
2,000,000
1,290,796
992,796
1,000,000
526,317
0
Cash Cash Spend Equity Assets
+440% +30% +116% +95%
----- End of picture text -----

A year of growth and investment

• Estimate

==> picture [960 x 35] intentionally omitted <==

==> picture [271 x 52] intentionally omitted <==

Growth:

Record revenue, sales, cash, share price, cap value (+44 to +116%) And investment:

Acquired and consolidated Thor laboratories into Uscom One off investments:

acquisition and integration (≈$1m)

BP+ and SpiroSonic product series prepared for revenue in 2017 (≈$0.5m) global corporate model established

Transformational $65m 5yr China agreement

Approaching profitability with two new device series for sale in 2017

==> picture [61 x 73] intentionally omitted <==

A year of growth and investment

==> picture [960 x 35] intentionally omitted <==

==> picture [123 x 53] intentionally omitted <==

“Growth as planned!”

==> picture [61 x 73] intentionally omitted <==

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [172 x 53] intentionally omitted <==

==> picture [123 x 53] intentionally omitted <==

" Investors can review Uscom’s progress in 2016 with satisfaction and look forward to the rewards of 2017 and beyond.

Uscom has invested in the future, and investors will share in the profits of this investment as we continue to meet our milestones.”

==> picture [61 x 73] intentionally omitted <==

A year of growth and investment

==> picture [960 x 35] intentionally omitted <==

==> picture [283 x 53] intentionally omitted <==

==> picture [127 x 152] intentionally omitted <==

==> picture [302 x 99] intentionally omitted <==

==> picture [167 x 98] intentionally omitted <==

==> picture [61 x 73] intentionally omitted <==

Unrecognised value

Uscom – devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [321 x 53] intentionally omitted <==

==> picture [324 x 284] intentionally omitted <==

==> picture [77 x 137] intentionally omitted <==

==> picture [171 x 182] intentionally omitted <==

==> picture [61 x 73] intentionally omitted <==

Real devices, real value, real revenue

Uscom – devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [299 x 52] intentionally omitted <==

==> picture [189 x 165] intentionally omitted <==

==> picture [254 x 75] intentionally omitted <==

Telemonitoring asthma and COPD

==> picture [215 x 152] intentionally omitted <==

==> picture [77 x 137] intentionally omitted <==

Digital ultrasonic spirometers Wireless connectivity Proprietary apps and software Diagnostic and therapeutic monitoring Leading pulmonary monitors in eHealth 450 sold into the US (2016) Growing global market

==> picture [40 x 46] intentionally omitted <==

==> picture [42 x 47] intentionally omitted <==

==> picture [148 x 145] intentionally omitted <==

==> picture [215 x 163] intentionally omitted <==

Uscom Phone App

==> picture [61 x 73] intentionally omitted <==

Uscom digital spirometers

Bringing patients and clinicians together – The digital eHealth future

SpiroReporter software

==> picture [960 x 35] intentionally omitted <==

==> picture [389 x 52] intentionally omitted <==

Delivering multiple products into multiple jurisdictions

1. Uscom Sydney 2. Uscom London 3. Uscom Budapest 4. Uscom LA 5. Uscom Shanghai

==> picture [709 x 259] intentionally omitted <==

----- Start of picture text -----

•
2 • [•] • • •
• ••
[•] •3
•
• • [•] •
• [•] • •
[•] • 4
• •• •• • 5
•
•
•
•
•
•
•
•
• [•]
----- End of picture text -----

==> picture [146 x 104] intentionally omitted <==

----- Start of picture text -----

•
1
----- End of picture text -----

Key Markets Asia

Europe Nth America

Focus FY 2017

==> picture [69 x 86] intentionally omitted <==

Asia – Establish CIIC US – BP+ and SpiroSonic release Global tSpiro partnerships

==> picture [960 x 35] intentionally omitted <==

==> picture [217 x 53] intentionally omitted <==

Medica – Taking Uscom products to the world

Three leading product lines

Global distribution

130,000 Delegates

5,000 Exhibitors New distributors in advance of regulatory approvals

Distribution Agreements

==> picture [343 x 240] intentionally omitted <==

----- Start of picture text -----

60
55
50
42
40
36
30
23
20
12
10
0
2013 2014 2015 2016 2017
----- End of picture text -----*

==> picture [204 x 202] intentionally omitted <==

==> picture [61 x 73] intentionally omitted <==

Distributors are feet on the ground - revenue

*Aniticipated

==> picture [960 x 35] intentionally omitted <==

==> picture [266 x 52] intentionally omitted <==

Uscom – CIIC China state owned partnership

CIIC to import $65m of Uscom devices and support regulatory over 5 yrs

Health spend from 6-12% of GDP 1.35b population in 31 provinces Revenue targets in China $20m

Uscom positioning to grow with China - $20m pa revenue target

==> picture [960 x 35] intentionally omitted <==

==> picture [450 x 52] intentionally omitted <==

Uscom owns approved manufacturing facilities in Sydney and Hungary

Currently

Future

 USCOM 1A and BP+ in Sydney

 SpiroSonic and BP+ in Hungary

 SpiroSonic in Hungary

==> picture [222 x 162] intentionally omitted <==

==> picture [124 x 161] intentionally omitted <==

==> picture [217 x 161] intentionally omitted <==

==> picture [232 x 161] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

==> picture [450 x 52] intentionally omitted <==

The path to global markets

Uscom has established in house skills in regulatory approval of medical devices

• Europe - CE

• China – CFDA

• USA - FDA 510k

• Multiple small jurisdictions (TGA etc.)

CE is also used for other countries as a basis for registration

==> picture [383 x 244] intentionally omitted <==

==> picture [61 x 73] intentionally omitted <==

==> picture [960 x 35] intentionally omitted <==

==> picture [237 x 53] intentionally omitted <==

Jurisdictions

==> picture [61 x 73] intentionally omitted <==

Products 2016 2017 CFDA CE FDA CFDA CE FDA 1 USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ 2 Uscom BP+ ★ ★ ★ ★ ★ ★ 3 Uscom BP+Reporter ★ ★ ★ ★ ★ ★ 4 SpiroSonic Flo ★ ★ ★ ★ ✓ ★ 5 Smart ★ ★ ★ ★ ✓ ★ 6 Mobile ★ ★ ★ ★ ✓ ★ 7 Pro ★ ★ ★ ★ ✓ ★ 8 SpiroReporter ★ ★ ★ ★ ✓ ★ 9 tSpiro ★ ★ ★ ★ ✓ ★ 10 SpiroApp ★ ★ ★ ★ ✓ ★	Products 2016 2017 CFDA CE FDA CFDA CE FDA 1 USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ 2 Uscom BP+ ★ ★ ★ ★ ★ ★ 3 Uscom BP+Reporter ★ ★ ★ ★ ★ ★ 4 SpiroSonic Flo ★ ★ ★ ★ ✓ ★ 5 Smart ★ ★ ★ ★ ✓ ★ 6 Mobile ★ ★ ★ ★ ✓ ★ 7 Pro ★ ★ ★ ★ ✓ ★ 8 SpiroReporter ★ ★ ★ ★ ✓ ★ 9 tSpiro ★ ★ ★ ★ ✓ ★ 10 SpiroApp ★ ★ ★ ★ ✓ ★	Products 2016 2017 CFDA CE FDA CFDA CE FDA 1 USCOM 1A ✓ ✓ ✓ ✓ ✓ ✓ 2 Uscom BP+ ★ ★ ★ ★ ★ ★ 3 Uscom BP+Reporter ★ ★ ★ ★ ★ ★ 4 SpiroSonic Flo ★ ★ ★ ★ ✓ ★ 5 Smart ★ ★ ★ ★ ✓ ★ 6 Mobile ★ ★ ★ ★ ✓ ★ 7 Pro ★ ★ ★ ★ ✓ ★ 8 SpiroReporter ★ ★ ★ ★ ✓ ★ 9 tSpiro ★ ★ ★ ★ ✓ ★ 10 SpiroApp ★ ★ ★ ★ ✓ ★
Products	2016	2017
	CFDA CE FDA	CFDA CE FDA
1 USCOM 1A	✓ ✓ ✓	✓ ✓ ✓
2 Uscom BP+	★ ★ ★	★ ★ ★
3 Uscom BP+Reporter	★ ★ ★	★ ★ ★
4 SpiroSonic Flo	★ ★ ★	★ ✓ ★
5 Smart	★ ★ ★	★ ✓ ★
6 Mobile	★ ★ ★	★ ✓ ★
7 Pro	★ ★ ★	★ ✓ ★
8 SpiroReporter	★ ★ ★	★ ✓ ★
9 tSpiro	★ ★ ★	★ ✓ ★
10 SpiroApp	★ ★ ★	★ ✓ ★

★ In preparation/submitted ★ Expected ✓ Achieved

==> picture [960 x 35] intentionally omitted <==

==> picture [283 x 53] intentionally omitted <==

==> picture [131 x 53] intentionally omitted <==

==> picture [112 x 135] intentionally omitted <==

==> picture [266 x 88] intentionally omitted <==

==> picture [167 x 98] intentionally omitted <==

Science – R&D - Manufacture – Regulatory – Market - Revenue

==> picture [61 x 73] intentionally omitted <==

Three revenue streams

==> picture [960 x 35] intentionally omitted <==

==> picture [344 x 52] intentionally omitted <==

==> picture [61 x 73] intentionally omitted <==

Mission - Capitalise on investments - profitability with growth HY 2017 results in February More products - Global launch BP+ (+2 products) Global launch SpiroSonic (+7 products) More Revenue - Continue USCOM sales growth Global pricing More and better distribution Cross distribute USCOM/BP+/SpiroSonic Reimbursement drive Global operations – Grow US, UK and European operations Grow China Market value - Grow company fundamentals and shareholder value

Uscom has a history of meeting our milestones

==> picture [960 x 35] intentionally omitted <==

==> picture [111 x 52] intentionally omitted <==

European Research Grant to Develop Lung Cancer Diagnostic

==> picture [203 x 119] intentionally omitted <==

==> picture [88 x 105] intentionally omitted <==

==> picture [115 x 151] intentionally omitted <==

==> picture [114 x 114] intentionally omitted <==

“To develop a simple breath test device for early diagnosis of lung cancer and a wide range of viral, microbial, neoplastic (cancer) and genetic diseases.”

Based on world leading digital, multi-path ultrasonic spirometer technology for measurement and analysis of respiratory flow.

==> picture [61 x 73] intentionally omitted <==

Uscom - global reputation for excellence in science

==> picture [960 x 35] intentionally omitted <==

==> picture [111 x 52] intentionally omitted <==

Closing 2016 with Record Manufacturing

December month - record manufactured units December quarter – record manufactured units ( 42% of full FY 2016 ) December half – up 28% on prior half 1000[th] USCOM 1A manufactured

==> picture [61 x 73] intentionally omitted <==

Uscom has a history of meeting our milestones

==> picture [960 x 35] intentionally omitted <==

==> picture [123 x 53] intentionally omitted <==

"Uscom has acquired global assets to ensure reliable revenue growth and long term profitability.

Our strategy is to efficiently deliver the devices we have developed into global markets.

Establish a culture of profitable performance and future shareholder dividends.”

==> picture [61 x 73] intentionally omitted <==

Uscom – Medical devices the experts use

==> picture [960 x 35] intentionally omitted <==

==> picture [123 x 53] intentionally omitted <==

“Continued growth as planned”

==> picture [61 x 73] intentionally omitted <==

Uscom – Medical devices the experts use

==> picture [960 x 132] intentionally omitted <==

==> picture [244 x 44] intentionally omitted <==

==> picture [183 x 40] intentionally omitted <==

==> picture [135 x 39] intentionally omitted <==

Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO

==> picture [960 x 50] intentionally omitted <==